ArticleCureus2025
Neuropsychiatric Systemic Lupus Erythematosus: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropsychiatric systemic lupus erythematosus (NPSLE) is a rare and poorly understood manifestation of systemic lupus erythematosus, encompassing a wide range of neurological and psychiatric symptoms. In order to highlight the diagnostic complexity and therapeutic challenges of NPSLE, this report presents the management of three distinct presentations. We retrospectively reviewed cases of three female patients with NPSLE admitted to a tertiary care hospital. Clinical presentation, diagnostic workup, treatment strategies, and outcomes were analyzed. Each case demonstrated unique NPSLE manifestations: acute confusional state in the setting of sepsis, cerebral vasculitis with retinal involvement, and catatonia. Treatments included high-dose corticosteroids, cyclophosphamide, and mycophenolate mofetil, with varying degrees of clinical improvement. NPSLE remains a diagnostic challenge due to its heterogeneity and lack of definitive biomarkers. Early recognition and individualized immunosuppressive treatment are essential for improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.